Table IV. Comparison of responses to atezolizumab plus bevacizumab between hepatocellular carcinoma in the immune-related adverse events (irAE) and non-irAE groups.

CR: Complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluated; ORR: objective response rate; DCR: disease control rate.